Amphastar Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.94 (market cap $868.62M), while Sezzle Inc trades at $125.04 (market cap $4.32B). The key difference: Sezzle Inc is far larger — about 5× Amphastar Pharmaceuticals Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SEZL | |
|---|---|---|
Market Cap | $868.62M | $4.32B |
Sector | Health | Technology |
52-Week High | $30.81 | $188.55 |
52-Week Low | $16.87 | $50.97 |
Enterprise Value | $1.27B | $4.36B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
Sezzle (SEZL) trades at $125.06, up 5.98% with strong recent earnings performance, beating estimates for three consecutive quarters. The stock shows bearish technical signals despite robust fundamentals including 72.36% gross margins and 30.35% net income margins. Recent Q2 2026 results showed 51.7% revenue growth to $149.7 million with raised full-year guidance, though the stock experienced significant volatility following the report.
The outlook remains positive with analyst consensus target of $158.29 representing 26.6% upside, though elevated valuation multiples and technical weakness present near-term headwinds. Execution on growth initiatives and margin maintenance will be critical for sustained appreciation amid competitive fintech landscape and market volatility risks.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →